Danaher Corporation (DHR)
Health Care2 articles
Price chart
Danaher Corporation (DHR) overview
Danaher is a life-sciences and diagnostics conglomerate. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Danaher Corporation trades on the NYSE under the ticker symbol DHR. As of the most recent market data, the stock was priced around $213.56, down 1.16% on the session, giving Danaher Corporation a market capitalization of roughly $150.13B.
Over the past 52 weeks, DHR has traded between $160.93 and $242.80. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 38.5, a common gauge of how richly the market prices the company's earnings. Danaher Corporation also pays a dividend, currently yielding around 74.00%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch DHR
As one of the larger companies in the Health Care sector, Danaher Corporation is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch DHR for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Because the S&P 500 is weighted by market value, Danaher Corporation's size means its share-price moves can also nudge the index as a whole, making DHR a stock that even index investors pay attention to.
Market Mood
Latest DHR news
JPMorgan Recommends Eli Lilly, AbbVie, Danaher as Top Healthcare Stocks
JPMorgan has identified Eli Lilly, AbbVie, and Danaher Corporation as top picks within the healthcare sector. Investors are currently overlooking these stocks, which may present buying opportunities. The recommendation suggests potential growth in these companies as market dynamics shift. This could lead to increased interest and investment in these healthcare stocks, impacting their market performance positively for investors. Eli Lilly (LLY), AbbVie (ABBV), and Danaher (DHR) are highlighted for consideration.
Read More: JPMorgan Recommends Eli Lilly, AbbVie, Danaher as Top Healthcare Stocks
Danaher (DHR) Sees Decline After Soft Segment Performance
Danaher Corporation (DHR) experienced a significant drop in stock value following unexpectedly weak performance in one of its business segments. The company's shares faced pressure as investors reacted to this news, leading to increased volatility. Although specific percentages and trading volumes were not disclosed, the market's response indicated investor concern over growth prospects. This situation matters for investors as it highlights the sensitivity of Danaher's stock price to segment performance and overall market confidence.
Read More: Danaher (DHR) Sees Decline After Soft Segment PerformanceMore Health Care stocks
Frequently asked questions
Is Danaher Corporation in the S&P 500?
Yes. Danaher Corporation (DHR) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is DHR in?
Danaher Corporation is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest DHR news?
This page collects recent Danaher Corporation (DHR) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Danaher Corporation's stock price?
As of the most recent market data, Danaher Corporation (DHR) traded at approximately $213.56. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Danaher Corporation's market cap?
Danaher Corporation has a market capitalization of roughly $150.13B, based on its most recent share price and shares outstanding.
What is DHR's P/E ratio?
DHR trades at a trailing price-to-earnings ratio of about 38.5. The P/E ratio compares a company's share price to its earnings per share.